City State Bank’s CRISPR Therapeutics CRSP Stock Holding History

City State Bank’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$545	Hold	10	–	–	﹤0.01%	774
2026 Q1	$476	Hold	10	–	–	﹤0.01%	752
2025 Q4	$524	Hold	10	–	–	﹤0.01%	730
2025 Q3	$648	Hold	10	–	–	﹤0.01%	706
2025 Q2	$486	Hold	10	–	–	﹤0.01%	714
2025 Q1	$340	Hold	10	–	–	﹤0.01%	721
2024 Q4	$394	Hold	10	–	–	﹤0.01%	692
2024 Q3	$470	Hold	10	–	–	﹤0.01%	699
2024 Q2	$540	Hold	10	–	–	﹤0.01%	688
2024 Q1	$1K	Hold	10	–	–	﹤0.01%	677
2023 Q4	$1K	Buy	+10	New	+$553	﹤0.01%	645
2023 Q3	–	Sell	-10	Closed	-$1K	–	693
2023 Q2	$1K	Buy	+10	New	+$567	﹤0.01%	667
2022 Q4	–	Sell	-10	Closed	-$1K	–	666
2022 Q3	$1K	Hold	10	–	–	﹤0.01%	631
2022 Q2	$1K	Hold	10	–	–	﹤0.01%	634
2022 Q1	$1K	Buy	+10	New	+$628	﹤0.01%	652

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

City State Bank's CRSP Position: Q2 2026 in Review

City State Bank held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 10 shares worth $545. The position accounts for ﹤0.01% of the portfolio, ranked #774.

City State Bank first reported a position in CRSP in Q1 2022 and has held it in 15 quarters since. The position peaked at $1K in Q1 2024. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

City State Bank held 10 shares of CRISPR Therapeutics worth $545 as of Q2 2026.
City State Bank left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of City State Bank's portfolio in Q2 2026, its #774 holding.
City State Bank first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 15 quarters since.
City State Bank's CRISPR Therapeutics position peaked at $1K in Q1 2024.
523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on City State Bank's 13F filing for Q2 2026, filed 14 Jul 2026.